European Stocks Muted as Novartis Shares Fall Most on Record

European stocks were steady Tuesday, but Novartis AG weighed on the market after its third clinical-trial setback in one week. The repeated trial failures create a negative near-term catalyst for Novartis and underscore pipeline-development risk for the pharmaceutical company.